Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes – a Danish nationwide observational study-Reference-Cited by-同舟云学术

Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes – a Danish nationwide observational study

Published:2022-03 Issue: Volume:14 Page:100308
ISSN:2666-7762
Container-title:The Lancet Regional Health - Europe
language:en
Short-container-title:The Lancet Regional Health - Europe

Author:

Falkentoft Alexander C.^ORCID,Andersen Julie,Malik Mariam Elmegaard,Selmer Christian,Gæde Peter Haulund,Staehr Peter Bisgaard,Hlatky Mark A.,Fosbøl Emil,Køber Lars,Torp-Pedersen Christian,Gislason Gunnar H.,Gerds Thomas Alexander,Schou Morten,Bruun Niels E.,Ruwald Anne-Christine

Publisher

Elsevier BV

Subject

Health Policy,Oncology,Internal Medicine

Reference41 articles.

1. Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland;Jackson;Diabetologia,2012

2. Association Between Socioeconomic Status and Mortality, Cardiovascular Disease, and Cancer in Patients With Type 2 Diabetes;Rawshani;JAMA internal medicine,2016

3. Socioeconomic position and first-time major cardiovascular event in patients with type 2 diabetes: a Danish nationwide cohort study;Falkentoft;European journal of preventive cardiology,2021

4. Socioeconomic position and health among persons with diabetes mellitus: a conceptual framework and review of the literature;Brown;Epidemiologic reviews,2004

5. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Davies;Diabetes care,2018

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regional socioeconomic deprivation associated with the use of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in adults with type 2 diabetes in Germany;Diabetes, Obesity and Metabolism;2024-07-09

2. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists;Diabetes and Vascular Disease Research;2024-07

3. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile;Expert Opinion on Drug Safety;2024-05-13

4. Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia;Diabetes, Obesity and Metabolism;2024-04-15

5. Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease;Diabetes Epidemiology and Management;2024-04